在I期临床试验中的有效性评估:终点和挑战
M A Gouda1, P A Ballesteros2, I Garrido-Laguna3
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
概括
第一期瘤学试验评估安全性和有效性,指导新药开发. 结合新的终点可以在早期药物开发中改善抗瘤活性评估.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 药物开发 药物开发
背景情况:
- 一期瘤学试验传统上侧重于安全性,但越来越多地包括治疗意图.
- 第一阶段试验中的有效性信号对将新瘤药物推进到第二阶段的决定产生重大影响.
- 在小,异质的I期种群中评估疗效需要灵活的终点评估.
研究的目的:
- 在I期瘤学试验中审查经典疗效终点的实用性和局限性.
- 探索在早期研究中评估抗瘤活性的新疗效终点的潜力.
- 为改善早期药物开发决策提供关于整合不同终点的指导.
主要方法:
- 在I期瘤学试验中对经典疗效终点 (例如客观应答率,无进展生存率,总生存率) 的审查.
- 在小型,异质的患者队伍中讨论有效性评估的挑战.
- 探索新兴和新的终点来评估抗瘤活性.
主要成果:
- 经典的终点在I期瘤学试验中存在局限性,原因是样本规模小和研究设计.
- 新的终点为抗瘤活性提供了有价值的见解,补充了传统的措施.
- 综合终点评估提高了在早期药物开发中对治疗疗效的评估.
结论:
- 第I期瘤学试验需要一个细微的方法来评估除了安全之外的疗效.
- 结合新的终点可以克服评估早期抗瘤反应的挑战.
- 在I期试验中优化终点策略对于有效的新型瘤药物开发至关重要.
相关概念视频
Clinical Trials: Overview
2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
111
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111
Drug Administration and Therapy Phases: Overview
402
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
402
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K


